TY - JOUR
T1 - Advances in the identification and validation of autism biomarkers
AU - Oakley, Beth
AU - Loth, Eva
AU - Jones, Emily
AU - Chatham, Christopher
AU - Murphy, Declan
N1 - Funding Information:
We acknowledge the AIMS-2-TRIALS consortium/collaborators, including experts contributing to this article: Evdokia Anagnostou, Celso Arango, Tobias Banaschewski, Simon Baron-Cohen, Christian Beckmann, Thomas Bourgeron, Linda S. Brady, Jan K. Buitelaar, Florence Campana, Tony Charman, Christine Ecker, Richard Delorme, Louise Gallagher, Lindsay M. Ham, Rosemary Holt, Mark H. Johnson, Irena Kadiu, Luke Mason, Grainne McAlonan, James C. McPartland, Hein Odendaal, Gahan Pandina, Mark P. Richardson, Herbert Roeyers, Maria Tome, Peter Scheiffele, Emily Simonoff, Priscilla Springer, Julian Tillmann and Terje Falck-Ytter. This work received support from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement no. 777394) for AIMS-2-TRIALS. This Joint Undertaking receives support from the EU’s Horizon 2020 programme, EFPIA, Autism Speaks, Autistica and SFARI.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - A decade on from the launch of the pioneering autism biomarker discovery initiative EU-AIMS, here we highlight advances in biomarker discovery and validation from the follow-on AIMS-2-TRIALS programme, which aims to improve the wellbeing and outcomes of autistic people through precision healthcare approaches.
AB - A decade on from the launch of the pioneering autism biomarker discovery initiative EU-AIMS, here we highlight advances in biomarker discovery and validation from the follow-on AIMS-2-TRIALS programme, which aims to improve the wellbeing and outcomes of autistic people through precision healthcare approaches.
UR - http://www.scopus.com/inward/record.url?scp=85137076635&partnerID=8YFLogxK
U2 - 10.1038/d41573-022-00141-y
DO - 10.1038/d41573-022-00141-y
M3 - Comment/debate
SN - 1474-1776
VL - 21
SP - 697
EP - 698
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 10
ER -